COMMENT
Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
Vertex Pharmaceuticals’ Trikafta/Kaftrio is currently the world’s first triple-combination cystic fibrosis therapy which is hitting its stride with recent approvals.
insight
How has AI helped in tackling Covid-19?
Many artificial intelligence tools have been developed in response to the Covid-19 pandemic, but their use has shown mixed results so far
Restrictive Medicare coverage spells continued uncertainty for Aduhelm
2021: a record year for orphan therapies